How the Largest IPO of 2025 Could Be Healthy for Your Portfolio

Medline completed a $6.3 billion IPO at $29/share that values the company at roughly $35.5 billion, with proceeds earmarked to pay down about $16.5 billion of pre-IPO debt. The Chicago-based medical-surgical supplier, which grew sales from $17.5 billion in 2020 to analyst projections of ~$30 billion (full-year 2026), touts strong margins (gross ~27.4%, operating ~8.5%, net ~4.8%), 18% long-term average sales growth and predominantly organic expansion. Analysts forecast EPS of $1.17 for 2025 and $1.52 for 2026, and free cash flow of $1.5 billion (2025) rising to $2.1 billion (2026), with FCF per share implied at ~$1.80 after debt paydown; key risks include a P/E ~28, customer concentration in hospitals (~70% of sales), and significant private-equity voting control and share retention.

Analysis

Market Structure: Medline (MDLN) is a direct winner — vertically integrated manufacturing + distribution with ~27% gross margin vs peers (MCK/CAH ~4%) gives immediate price/margin advantage and the ability to squeeze low-margin distributors. Hospitals (70% of sales) and private-label manufacturers also benefit; legacy distributors (McKesson MCK, Cardinal CAH, Owens & Minor OMI) face margin and share pressure, particularly in high-frequency consumables where next‑day delivery and private label win. Expect incremental share shift of 2–5ppt annually in core medsurg categories if Medline converts 1–3% of large hospital spend per year.

Risk Assessment: Key tail risks are PE lock-up selling (large holders ~50% with 180-day lock-up expiry), interest-rate sensitivity on remaining ~$16.5B debt, and regulatory/antitrust scrutiny if share gains accelerate; reimbursement cuts or large hospital purchasing consolidations are 5–15% downside scenarios. Near term (days–months) focus is lock-up and next quarterly report showing how the $6.3B IPO proceeds reduced leverage; long term (3–5 years) execution vs TAM ($375B) matters — failure to sustain ~8–14% organic growth would re-rate valuation.

Trade Implications: Trade size modestly long MDLN (1–3% portfolio) for 6–12 months to capture FCF-led deleveraging and potential multiple re‑rating, financed by reducing exposure to CAH/OMI (reduce 20–30% over 3 months). Consider pair trades: long MDLN vs short CAH or OMI to isolate sector share shift; use 6–12 month call spreads on MDLN to cap premium and buy 180–210 day put spreads ahead of lock-up expiry as hedge. Fixed income: MDLN debt paydown could tighten nearby high‑yield healthcare spreads — long selective single‑name hospital-supplier credit (where yields < spread compression) with 6–12 month horizon.

Contrarian Angles: Consensus underestimates governance risk — PE owners retain ~60% voting control which can delay liquidity events and compress float-driven volatility; conversely market may be underpricing sustainable margin premium versus peers given vertically integrated model. Historical parallel: private-equity built distributors (e.g., prior OMI cycles) sometimes see rapid margin reversion when competitors respond — monitor competitor pricing actions within 90 days post-IPO. Unintended consequence: aggressive share gains could trigger bulk purchasing contracts from large health systems that lower ASPs while increasing volume, capping unit economics.

Key Decisions for Investors

• Establish a 1.5–3% long position in Medline (MDLN) now (scale in over 4–6 weeks) aiming for a 12-month target of +25–40% if FCF > $1.8/share and net debt falls by ≥$4–6B on next report; set a hard stop-loss at -20% from cost and trim to 50% position if lock-up sellers materially increase float.
• Initiate a market-neutral pair: long MDLN (1% NAV) and short Cardinal Health (CAH) or Owens & Minor (OMI) (1% NAV) to capture expected 2–5ppt market-share shift; rebalance after each quarterly report or if relative performance diverges by >10% within 3 months.
• Buy a 6–12 month MDLN call spread (e.g., buy ATM, sell 20–30% OTM) sized to 0.5–1% NAV to play deleveraging and multiple expansion while limiting premium; concurrently purchase a 180–210 day put spread as hedge around the 180-day lock-up expiry to cap downside from potential PE selling.
• Reduce exposure to low-margin distributors (MCK/CAH/OMI) by 20–30% over the next 3 months and reallocate proceeds to private‑label/high‑margin healthcare suppliers or selective single-name credit that will benefit if Medline compresses sector spreads; reassess after Medline’s next earnings and lock-up expiry.